drugset / Trial / NCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

NCT03114371 ↗

Completed 40 enrolled University Hospital, Toulouse
RandomizedParallel-groupDouble-blindTreatment

Summary

Positive results in preclinical and clinical studies in adults and infants with Prader-Willi syndrome lead investigators to set up a new study in children with Prader-Willi syndrome. The objective of this study is to document effects of oxytocin intranasal administrations on behavioural troubles in children with Prader-Willi syndrome aged from 3 to 12 years.

Timeline

Start
2016-11-28
Primary completion
2019-01
Completion
2019-01-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 8 iu Intranasal
Subject Oxytocin Peptide 16 iu Intranasal

Indications